Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -199.30% is 80% above its 5-year average of -977.62%, near the high end of its 5-year range (-4992.09%–-66.94%).
45.04% below its 12-month average of -137.41%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -44.18%.
RETURN ON ASSETS (ROA)
-199.30%
RETURN ON ASSETS (ROA) AVG TTM
-137.41%
RETURN ON ASSETS (ROA) AVG 3Y
-109.57%
RETURN ON ASSETS (ROA) AVG 5Y
-977.62%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-45.04%
CURRENT VS 3Y AVG
-81.88%
CURRENT VS 5Y AVG
+79.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-610.64%
vs the sector median at left
bioAffinity Technologies, Inc.
Market Cap
$2.64M
Return on Assets (ROA)
-199.30%
TTM Avg
-137.41%
3Y Avg
-109.57%
5Y Avg
-977.62%
Market Cap
$2.60M
Return on Assets (ROA)
-154.47%
TTM Avg
-121.84%
3Y Avg
-88.87%
5Y Avg
-75.91%
Market Cap
$2.76M
Return on Assets (ROA)
-107.18%
TTM Avg
-105.74%
3Y Avg
-98.21%
5Y Avg
-95.08%
Market Cap
$2.51M
Return on Assets (ROA)
-143.82%
TTM Avg
-140.13%
3Y Avg
-102.17%
5Y Avg
-81.19%
Market Cap
$2.43M
Return on Assets (ROA)
-228.77%
TTM Avg
-130.86%
3Y Avg
-126.84%
5Y Avg
-140.90%
Market Cap
$2.38M
Return on Assets (ROA)
-56.04%
TTM Avg
-32.94%
3Y Avg
-18.68%
5Y Avg
-12.05%
Market Cap
$2.35M
Return on Assets (ROA)
-64.42%
TTM Avg
-79.57%
3Y Avg
-65.34%
5Y Avg
-858.61%
Market Cap
$3.02M
Return on Assets (ROA)
-238.27%
TTM Avg
-211.11%
3Y Avg
-146.32%
5Y Avg
-173.65%
Market Cap
$2.07M
Return on Assets (ROA)
-439.95%
TTM Avg
-322.44%
3Y Avg
-242.34%
5Y Avg
-192.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.64M | -199.30% | -137.41% | -109.57% | -977.62% |
| iSpecimen Inc. (ISPC)vs › | $2.60M | -154.47% | -121.84% | -88.87% | -75.91% |
| Jaguar Health, Inc. (JAGX)vs › | $2.76M | -107.18% | -105.74% | -98.21% | -95.08% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.51M | -143.82% | -140.13% | -102.17% | -81.19% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.43M | -228.77% | -130.86% | -126.84% | -140.90% |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | -56.04% | -32.94% | -18.68% | -12.05% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.35M | -64.42% | -79.57% | -65.34% | -858.61% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.02M | -238.27% | -211.11% | -146.32% | -173.65% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.07M | -439.95% | -322.44% | -242.34% | -192.54% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | -80.08% | -84.48% | -250.02% | -187.49% |
ROA
-199.3%
ROE
-402.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -136.03% |
| 2024-12-31 | -138.79% |
| 2023-12-31 | -96.54% |
| 2022-12-31 | -66.94% |
| 2021-12-31 | -435.31% |
| 2020-12-31 | -4992.09% |
| 2019-12-31 | -502.04% |
